LAUSR

Key Points Question Who is at risk of diminished quality of life (QOL) in extended follow-up of breast cancer survivors treated with intensive systemic treatment? Findings Among 455 participants included in this secondary analysis of a phase 3 randomized clinical trial, adding bevacizumab to chemotherapy was not negatively associated with QOL at 18 months. A substantial proportion of patients reported problems related to pain or discomfort and anxiety or depression; receiving mastectomy with radiation as well as identifying as Asian, Black, or American Indian or Alaska Native were associated with lower QOL. Meaning These findings suggest that early intervention and referral to supportive resources is critical for survivors at risk of experiencing diminished QOL, especially among individuals from underrepresented racial and ethnic groups and those undergoing extensive local therapy.